A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Exclusion Criteria

• •Presence of any hematological malignancy other than ET, PMF, or post-ET MF.
• •Active invasive malignancy over the previous 2 years.
• •Active HBV/HCV, HIV.
• •History of clinically significant or uncontrolled cardiac disease.
• •Has undergone any prior allogenic or autologous stem-cell transplantation or such transplantation is planned.
• •Laboratory values outside the Protocol-defined ranges.
• •Participants undergoing treatment with G-CSF, GM-CSF, or TPO-R agonists at any time within 4 weeks before the first dose of study treatment.
• •Prior history of major bleeding, or thrombosis within the last 3 months prior to study enrollment.
• •Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, antibody, or hypomethylating agent used to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.
• •For TGBs only: Undergoing treatment with a potent/strong inhibitor or inducer of CYP 3A4/5 within 14 days or 5 half-lives (whichever is longer) before the first dose of study treatment, or expected to receive such treatment during the study.